BridgeBio Pharma Inc

Effective on February 19, 2025, our board of directors reassigned the Company’s Principal Financial Officer and Principal Accounting Officer roles from Brian Stephenson, Ph.D., and appointed them to Thomas Trimarchi, Ph.D., and Maricel M. Apuli, respectively, in each case as contemplated by Rule 16a-1 of the Exchange Act.

Dr. Trimarchi, age 40, joined the Company in April 2018 as the Chief Product Officer. In July 2024, he was promoted as President and Chief Operating Officer of the Company. Dr. Trimarchi leads cross-functional activities at the Company to develop a centralized operation across the late-stage pipeline prioritizing efficiency, rigor, and scale. He is also a board member of ML Bio, an affiliate of the Company focused on developing BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), since November 2021. Prior to joining the Company, Dr. Trimarchi worked in corporate strategy at Regeneron Pharmaceuticals, Inc. from 2017 to 2018. From 2015 to 2017, Dr. Trimarchi was an equity analyst in the Global Investment Research division at Goldman Sachs. Dr. Trimarchi received a B.S. in Biology from the University of Vermont and a Ph.D. from NYU Grossman School of Medicine.

Ms. Apuli, age 48, joined the Company in September 2021 as Vice President, Corporate Controller. In January 2023, she was promoted to Chief Accounting Officer of the Company. Ms. Apuli oversees the Company’s accounting, financial reporting, tax and SOX compliance, and finance-related functions. Prior to joining the Company, Ms. Apuli was Vice President, Corporate Controller at Guardant Health, Inc. from December 2019 to September 2021. From 2018 to 2019, Ms. Apuli was Vice President of Finance, Controller at Arlo Technologies, Inc. From 2013 to 2018, Ms. Apuli was Director of Accounting at KLA Corporation. Earlier in her career, she served as a Senior Audit Manager at PricewaterhouseCoopers LLP (U.S.). Ms. Apuli received a B.S. in Accountancy from the University of Santo Tomas-Legazpi.

Except as described above, there are no understandings or arrangements between each of Dr. Trimarchi and Ms. Apuli and any other person pursuant to which he or she was appointed as Principal Financial Officer or Principal Accounting Officer of the Company, as applicable. Neither Dr. Trimarchi nor Ms. Apuli has material interest in any transaction or proposed transaction in which the Company is or is to be a party. Neither Dr. Trimarchi nor Ms. Apuli has a family relationship with any director or executive officer of the Company.

Rule 10b5-1 Trading Plans

Note: The following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act) or director who entered into, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended December 31, 2024: